Literature DB >> 23994522

Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Chun Chen1, William T Baumann, Robert Clarke, John J Tyson.   

Abstract

Breast cancer cells develop resistance to endocrine therapies by shifting between estrogen receptor (ER)-regulated and growth factor receptor (GFR)-regulated survival signaling pathways. To study this switch, we propose a mathematical model of crosstalk between these pathways. The model explains why MCF7 sub-clones transfected with HER2 or EGFR show three GFR-distribution patterns, and why the bimodal distribution pattern can be reversibly modulated by estrogen. The model illustrates how transient overexpression of ER activates GFR signaling and promotes estrogen-independent growth. Understanding this survival-signaling switch can help in the design of future therapies to overcome resistance in breast cancer.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  17β-estradiol; AKT; Breast cancer; CCS; CSC; E2; E2-bound estrogen receptor; E2:ER; EGFR; ER; ER-P; Endocrine resistance; Estrogen receptor signaling; FCS; GFR; Growth factor receptor signaling; HER2; MAPK; Mathematical modeling; NFκB; PI3K; a serine/threonine-specific protein kinase, also known as Protein Kinase B (PKB); cancer stem cell; charcoal-stripped fetal-calf serum; epidermal growth factor receptor; estrogen receptor; fetal calf serum; growth factor receptor; human epidermal growth factor receptor-2; mTOR; mammalian target of rapamycin; mitogen activated protein kinases; nuclear factor kappa-light-chain-enhancer of activated B cells; phosphatidylinositide 3-kinases; phosphorylated estrogen receptor

Mesh:

Substances:

Year:  2013        PMID: 23994522      PMCID: PMC3893882          DOI: 10.1016/j.febslet.2013.08.022

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  48 in total

Review 1.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.

Authors:  A Singh; J Settleman
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

Review 2.  Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications.

Authors:  J M W Gee; V E Shaw; S E Hiscox; R A McClelland; N K Rushmere; R I Nicholson
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

3.  An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression.

Authors:  N P Bates; H C Hurst
Journal:  Oncogene       Date:  1997-07-24       Impact factor: 9.867

4.  Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.

Authors:  Julia M W Gee; Robert I Nicholson; Denise Barrow; Carol M Dutkowski; Lindy Goddard; Nicola J Jordan; Richard A McClelland; Janice M Knowlden; Hayley E Francies; Stephen E Hiscox; Iain R Hutcheson
Journal:  Horm Mol Biol Clin Investig       Date:  2011-03-01

Review 5.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

6.  MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo.

Authors:  Y Liu; D el-Ashry; D Chen; I Y Ding; F G Kern
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

7.  Progression of human breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo.

Authors:  R Clarke; N Brünner; B S Katzenellenbogen; E W Thompson; M J Norman; C Koppi; S Paik; M E Lippman; R B Dickson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

Review 8.  Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

Authors:  Robert Clarke; Minetta C Liu; Kerrie B Bouker; Zhiping Gu; Richard Y Lee; Yuelin Zhu; Todd C Skaar; Bianca Gomez; Kerry O'Brien; Yue Wang; Leena A Hilakivi-Clarke
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

Authors:  Iain R Hutcheson; Janice M Knowlden; Tracie-Ann Madden; Denise Barrow; Julia M W Gee; Alan E Wakeling; Robert I Nicholson
Journal:  Breast Cancer Res Treat       Date:  2003-09       Impact factor: 4.872

10.  Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.

Authors:  Jill Bayliss; Amy Hilger; Prakash Vishnu; Kathleen Diehl; Dorraya El-Ashry
Journal:  Clin Cancer Res       Date:  2007-12-01       Impact factor: 12.531

View more
  16 in total

Review 1.  Systems biology: perspectives on multiscale modeling in research on endocrine-related cancers.

Authors:  Robert Clarke; John J Tyson; Ming Tan; William T Baumann; Lu Jin; Jianhua Xuan; Yue Wang
Journal:  Endocr Relat Cancer       Date:  2019-06       Impact factor: 5.678

2.  Estrogen receptor-α signaling and localization regulates autophagy and unfolded protein response activation in ER+ breast cancer.

Authors:  Katherine L Cook; Robert Clarke
Journal:  Receptors Clin Investig       Date:  2014

Review 3.  Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Authors:  Mark A Feitelson; Alla Arzumanyan; Rob J Kulathinal; Stacy W Blain; Randall F Holcombe; Jamal Mahajna; Maria Marino; Maria L Martinez-Chantar; Roman Nawroth; Isidro Sanchez-Garcia; Dipali Sharma; Neeraj K Saxena; Neetu Singh; Panagiotis J Vlachostergios; Shanchun Guo; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Alan Bilsland; Amedeo Amedei; Elena Niccolai; Amr Amin; S Salman Ashraf; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Katia Aquilano; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; W Nicol Keith; Somaira Nowsheen
Journal:  Semin Cancer Biol       Date:  2015-04-17       Impact factor: 15.707

4.  Mathematical models of the transitions between endocrine therapy responsive and resistant states in breast cancer.

Authors:  Chun Chen; William T Baumann; Jianhua Xing; Lingling Xu; Robert Clarke; John J Tyson
Journal:  J R Soc Interface       Date:  2014-05-07       Impact factor: 4.118

5.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

Review 6.  Role of nuclear receptors in breast cancer stem cells.

Authors:  Alessio Papi; Marina Orlandi
Journal:  World J Stem Cells       Date:  2016-03-26       Impact factor: 5.326

Review 7.  Endocrine resistance in breast cancer--An overview and update.

Authors:  Robert Clarke; John J Tyson; J Michael Dixon
Journal:  Mol Cell Endocrinol       Date:  2015-10-09       Impact factor: 4.102

8.  In Vivo Phosphoproteome Analysis Reveals Kinome Reprogramming in Hepatocellular Carcinoma.

Authors:  Liangliang Ren; Chaoying Li; Youliang Wang; Yan Teng; Huichuan Sun; Baocai Xing; Xiao Yang; Ying Jiang; Fuchu He
Journal:  Mol Cell Proteomics       Date:  2018-02-22       Impact factor: 5.911

Review 9.  Personalized Medicine for Neuroblastoma: Moving from Static Genotypes to Dynamic Simulations of Drug Response.

Authors:  Jeremy Z R Han; Jordan F Hastings; Monica Phimmachanh; Dirk Fey; Walter Kolch; David R Croucher
Journal:  J Pers Med       Date:  2021-05-11

Review 10.  Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancer.

Authors:  Qinqin Li; Zhenghuan Rao; Yanlin Wang; Lei Zhang; Jing Chen; Runlan Wan; Alexander Tobias Teichmann
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.